{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:19:22Z","timestamp":1774977562189,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmcl.2026.130627","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:49:02Z","timestamp":1773906542000},"page":"130627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["New salidroside-furoxan hybrids as potential agents inhibit triple-negative breast cancer"],"prefix":"10.1016","volume":"136","author":[{"given":"Bing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130627_bb0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple - negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Ann Rev Pathol: Mech Dis"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130627_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cmet.2022.11.014","article-title":"The achilles heel of TNBCs: Ferroptosis heterogeneity","volume":"35","author":"Jiang","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.bmcl.2026.130627_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","article-title":"The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality","volume":"67","author":"Papadimitriou","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bmcl.2026.130627_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109150","article-title":"Exploration of chromenone-based ligands as DNA G-quadruplex targets in triple-negative breast cancer","volume":"166","author":"Mock","year":"2025","journal-title":"Bioorg Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130627_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/scipharm93010006","article-title":"Targeting c-MYC G-quadruplexes for cancer treatment with small molecules","volume":"93","author":"Thumpati","year":"2025","journal-title":"Sci Pharm"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130627_bb0030","article-title":"Expanding the toolbox of target directed bio-orthogonal synthesis: in situ direct macrocyclization by DNA templates","volume":"62","author":"Chaudhuri","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"issue":"17","key":"10.1016\/j.bmcl.2026.130627_bb0035","first-page":"5349","article-title":"Multiple mechanisms of salidroside on anti - tumor effects","volume":"25","author":"Wang","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.bmcl.2026.130627_bb0040","doi-asserted-by":"crossref","unstructured":"Sun SY, Tuo QH, Li DX, et al. Antioxidant effects of salidroside in the cardiovascular system. Evid-Based Compl Alt 2020; 2020:9568647, Evid Based Complement Alternat Med.","DOI":"10.1155\/2020\/9568647"},{"key":"10.1016\/j.bmcl.2026.130627_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.974775","article-title":"Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases","volume":"13","author":"Han","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130627_bb0050","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s12013-025-01667-9","article-title":"Salidroside prevents keloid fibroblast aggressive progression by upregulating miR-26a-5p to inhibit JAG1","volume":"83","author":"Qin","year":"2025","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.bmcl.2026.130627_bb0055","doi-asserted-by":"crossref","unstructured":"Zhao G, Shi AP, Fan ZM, et al. Salidroside inhibits the growth of human breast cancer in vitro and in vivo. Oncol Rep 2015;33(5):2553\u20132560.","DOI":"10.3892\/or.2015.3857"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130627_bb0060","first-page":"1969","article-title":"Salidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2\/STAT3 signaling pathway","volume":"54","author":"Huang","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.bmcl.2026.130627_bb0065","doi-asserted-by":"crossref","unstructured":"Hu XL, Zhang XQ, Qiu SF, et al. Salidroside induces cell - cycle arrest and apoptosis in human breast cancer cells. Biochem Biophys Res Commun 2010;398(1):62\u201367.","DOI":"10.1016\/j.bbrc.2010.06.033"},{"key":"10.1016\/j.bmcl.2026.130627_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109726","article-title":"Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K\/Akt\/mTOR pathway","volume":"122","author":"Rong","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2026.130627_bb0075","doi-asserted-by":"crossref","unstructured":"Yu G, Li N, Zhao Y, et al. Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway. Oncol Lett 2018;15(5):6513\u20136518.","DOI":"10.3892\/ol.2018.8090"},{"key":"10.1016\/j.bmcl.2026.130627_bb0080","doi-asserted-by":"crossref","unstructured":"Wang JT, Yang ZQ, Feng ZL, et al. Synthesis of salidroside derivatives at C4 position of benzene ring and its effect on Hep3B cell viability. Chem Biol Drug Des 2025;105(6):e70131.","DOI":"10.1111\/cbdd.70131"},{"issue":"18","key":"10.1016\/j.bmcl.2026.130627_bb0085","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b01672","article-title":"Nitric oxide donor-based cancer therapy: advances and prospects","volume":"60","author":"Huang","year":"2017","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.bmcl.2026.130627_bb0090","doi-asserted-by":"crossref","first-page":"12446","DOI":"10.1021\/acs.jmedchem.3c00954","article-title":"Design, synthesis, and biological evaluation of Esculetin-Furoxan-DEAC ternary hybrids for anti-triple negative breast Cancer","volume":"66","author":"Wen","year":"2023","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130627_bb0095","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1039\/D4MD00281D","article-title":"Furoxan-piplartine hybrids as effective NO donors and ROS inducers in PC3 cancer cells: design, synthesis, and biological evaluation","volume":"15","author":"Brustolin Braga","year":"2024","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmcl.2026.130627_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117856","article-title":"Discovery of hybrids of bisbibenzyl with furoxan as lysosomotropic agents for the treatment of drug-resistant non-small-cell lung cancer","volume":"296","author":"Sun","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130627_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112386","article-title":"Novel NO-releasing scopoletin derivatives induce cell death via mitochondrial apoptosis pathway and cell cycle arrest","volume":"200","author":"Shi","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130627_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113701","article-title":"Design, synthesis and biological activity evaluation of novel scopoletin-NO donor derivatives against MCF-7 human breast cancer in vitro and in vivo","volume":"224","author":"Yu","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2026.130627_bb0115","doi-asserted-by":"crossref","first-page":"13089","DOI":"10.1021\/acs.jmedchem.4c01070","article-title":"Discovery of NO donor-Aurovertin hybrids as dual ferroptosis and apoptosis inducers for treating triple negative breast cancer","volume":"67","author":"Ma","year":"2024","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130627_bb0120","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/acsptsci.3c00329","article-title":"Coumarin-Furoxan hybrid suppressed the proliferation and metastasis of triple-negative breast Cancer by activating mitochondrial stress and cell apoptosis","volume":"7","author":"Li","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bmcl.2026.130627_bb0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejmech.2017.05.046","article-title":"Novel NO-releasing plumbagin derivatives: design, synthesis and evaluation of anti-proliferative activity","volume":"137","author":"Bao","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130627_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lfs.2016.06.016","article-title":"Redox homeostasis of breast cancer lineages contributes to differential cell death response to exogenous hydrogen peroxide","volume":"158","author":"Hecht","year":"2016","journal-title":"Life Sci"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:30:39Z","timestamp":1774974639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S0960894X26000946"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130627","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New salidroside-furoxan hybrids as potential agents inhibit triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130627"}}